Milestone Scientific Partners with Etiome for Innovations in Chronic Disease Detection and Treatment

Etiome Welcomes New Chief Scientific Officer to Drive Disease Detection and Intervention Innovations

Etiome, a pioneering biotechnology firm based in Cambridge, Massachusetts, announces the appointment of Jean Lachowicz, Ph.D., MBA, as its Chief Scientific Officer. This strategic move aims to bolster Etiome’s groundbreaking Temporal Biodynamics™ platform, which is poised to transform the early detection and preemptive treatment of chronic diseases. With the rise of chronic and progressive health conditions, the need for innovative approaches to disease management is more critical than ever. Lachowicz’s expertise in drug discovery and development will enhance Etiome's efforts to create Biostaged Medicines that not only target existing health issues but also aim to prevent their progression.

Dr. Lachowicz brings nearly three decades of experience in the pharmaceutical industry, having held key roles at prominent companies such as Schrodinger, Celgene, Merck, and Schering Plough. Her extensive background in translating research into FDA-approved therapies across various therapeutic areas—including neurology, oncology, and immunology—positions her well to lead Etiome's scientific vision. Avak Kahvejian, Ph.D., Etiome’s Founding CEO, commends Lachowicz for her proven track record in advancing medicines from concept to market. This appointment emphasizes Etiome’s commitment to redefining how diseases are identified and treated, focusing on the potential of early interventions to significantly improve patient outcomes.

The Temporal Biodynamics™ platform is central to Etiome’s mission, as it seeks to offer a comprehensive understanding of disease progression. By identifying therapeutic targets and biomarkers, the platform enables the development of timely and effective treatments tailored to individual patient needs. The introduction of Biostaged Medicines aligns with Etiome's goal of preemptive healthcare—intervening before diseases reach critical stages. As Dr. Lachowicz steps into her new role, the company sets its sights on building a robust pipeline of innovative solutions, which could pave the way for a paradigm shift in how chronic diseases are approached.

In related news, BrioHealth Solutions marks a significant achievement by enrolling its 100th patient in the INNOVATE Trial for the BrioVAD® System, a left ventricular assist device designed for advanced heart failure care. This trial unites leading heart centers nationwide, aiming to enhance treatment options for patients facing severe cardiac challenges. CEO Chen Chen, Ph.D., emphasizes that this milestone not only improves survival rates but also enhances patients' quality of life, underscoring the importance of innovative healthcare solutions in addressing complex medical conditions.

As both Etiome and BrioHealth advance their respective missions, the biotechnology and medical device sectors continue to witness a surge in innovative approaches aimed at improving patient health outcomes through early intervention and enhanced treatment options.